Drug intelligence / Profile preview

ST-901

Development stage: Preclinical
Lead developer: Syremis Therapeutics
Modality: Small Molecules

Overview

ST-901 is a small molecule NMDA receptor antagonist under development by Syremis Therapeutics for the treatment of major depressive disorder (MDD) and bipolar depression. By targeting the N-methyl-D-aspartate (NMDA) receptor, a glutamate-gated ion channel, ST-901 aims to modulate glutamatergic signaling, which is a key pathway in the pathophysiology of mood disorders and a target for rapid-acting antidepressant effects. The program is currently in the IND-enabling stage, positioning it as a potential next-generation therapy for patients who have not achieved adequate relief from standard-of-care treatments.

Targets

NMDAR (Glutamate receptor ionotropic, NMDA)

Beyond the preview

Go deeper on ST-901.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ST-901.

Explore the full profile